Apimeds Pharmaceuticals US Inc. and MindWave Innovations Inc. have signed a merger agreement to combine their businesses, creating an enterprise that spans advanced biotechnology and institutional digital-asset treasury solutions. The merged entity will integrate Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-driven Bitcoin treasury and digital asset yield generation platform. The transaction is supported by a private investment of up to $100 million to advance Apimeds' clinical programs and expand MindWave's digital asset infrastructure. Following the merger, Apimeds' assets and liabilities will be transferred to a wholly owned subsidiary, where its core business will continue.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201743056) on December 01, 2025, and is solely responsible for the information contained therein.